Biophytis SA Sponsored ADR BPTSY

Biophytis expands alliance with LynxKite to advance AI-driven drug discovery. Alliance expansion supports Biophytis drug discovery innovation with moderate trajectory effects.

Biophytis expands alliance with LynxKite to accelerate AI-driven drug discovery targeting next-generation longevity therapeutics. Expanded LynxKite alliance strengthens AI drug discovery pipeline for longevity therapeutics.

Biophytis SA is focusing on restoring mobility in patients with obesity through its innovative therapies. The company aims to address the challenges faced by this demographic, particularly in relation to mobility and overall health. By developing targeted treatments, Biophytis seeks to improve the quality of life for these patients and potentially tap into a significant market opportunity. The initiative to restore mobility in obese patients represents a significant strategic move that could enhance Biophytis's market position and investor sentiment.

Biophytis SA has confirmed the initiation of its Phase 2 OBA clinical trial focused on obesity. This trial aims to evaluate the efficacy and safety of its drug candidate in treating obesity-related conditions. The company is advancing its research efforts to address the growing obesity epidemic, which poses significant health risks globally. The launch of a Phase 2 clinical trial represents a significant strategic move that could impact Biophytis's future performance and market position.

Biophytis SA announced the launch of a new clinical development program named OBA with potential treatment for obesity. The company also shared positive results from the Phase 2/3 COVA trial. The announcement of a new clinical development program and positive trial results are significant events that could impact the company's future trajectory and market performance.

Biophytis S.A. announces phase II obesity study with BIO101, stock surges 63.1% in after-market hours. Launch of phase II study with potential game-changing impact on future market performance.

Biophytis SA announced new preclinical results for its investigational drug BIO101, showing that its combination with GLP-1 significantly improved muscle strength and mobility in diet-induced obese mice. This data was presented at the 15th International Conference on Frailty and Sarcopenia Research. Previous clinical trials indicated that BIO101 also benefited human patients with obesity. With obesity affecting nearly one billion people globally and linked to muscle strength decline, Biophytis aims to address this unmet medical need through its Phase 2 OBA clinical trial. The combination of BIO101 and GLP-1 shows significant potential to address a critical health issue, likely influencing Biophytis's market position and investor sentiment.

Biophytis SA announced the publication of Phase 2 clinical trial results for BIO101 in the Journal of Cachexia, Sarcopenia and Muscle, demonstrating promising efficacy and excellent safety in treating sarcopenia. The company is progressing towards Phase 3 trial readiness and engaging with international pharmaceutical partners, particularly in China. Sarcopenia affects millions globally, with no current therapeutic solutions, positioning Biophytis as a leader in this indication. The publication of positive Phase 2 results and readiness for Phase 3 trials could significantly enhance Biophytis's market position and investor sentiment.

Biophytis SA announced its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR), highlighting its commitment to addressing age-related conditions and showcasing its research initiatives in this field. Participation in a significant conference may enhance visibility and networking opportunities, potentially influencing future collaborations and research advancements.

Biophytis SA has outlined its strategic outlook for 2025, focusing on the launch of the OBA clinical development program for obesity treatment and strengthening its financial structure. Key initiatives include a licensing agreement with Blanver, exclusive negotiations with a major Chinese pharmaceutical company, and a co-development agreement with AskHelpU for ALS. The company plans to initiate a Phase 2 study for its lead drug candidate, BIO101 (20-Hydroxyecdysone), in obesity and launch Phase 3 of its SARA clinical program for sarcopenia. CEO Stanislas Veillet emphasized the commitment to addressing public health issues in obesity and sarcopenia, with a focus on expanding partnerships globally. The strategic initiatives and partnerships outlined are likely to significantly impact Biophytis' future performance and market positioning.

Biophytis SA has entered into a co-development agreement with AskHelpU to address rare neuromuscular diseases in China. This collaboration aims to leverage both companies' expertise to enhance treatment options and accelerate the development of therapies in this underserved market. The partnership represents a significant strategic move that could enhance Biophytis's market position and growth potential in a critical therapeutic area.

Biophytis SA has entered exclusive negotiations with a Chinese pharmaceutical company to license its drug BIO101, which is aimed at treating age-related diseases. This partnership could enhance Biophytis's market reach and accelerate the development of BIO101, potentially leading to significant advancements in its therapeutic applications. The licensing agreement with a Chinese pharmaceutical company could significantly enhance Biophytis's market presence and development capabilities for BIO101.

Biophytis SA publishes first-half financial results and updates on business activities, including the launch of an obesity program and an exclusive licensing agreement for Latin America. The article highlights significant developments in clinical programs and partnerships that could transform the company's future.

Immunis partners with Springbok Analytics for MRI-based AI muscle analysis in sarcopenia trial using Immuna therapy derived from human cell secretions. Phase I/II trial aims to reverse muscle atrophy in aged population with knee osteoarthritis. The partnership with Springbok Analytics and the potential positive results from the Phase I/II trial could significantly impact Biophytis SA's future in the sarcopenia treatment market.

Biophytis signs two contracts with local agents in Asia to expand its presence and accelerate the deployment of BIO101 in Japan, South Korea, China, and Southeast Asia. The signing of contracts in strategic markets like Japan and China is expected to have a significant impact on Biophytis' future growth and market performance.

Biophytis obtains FDA approval for Phase II OBA obesity study with BIO101 to improve muscle strength in lower limbs, overseen by obesity expert Marc-André Cornier, with potential expansion to European sites and preliminary results expected by 2025. The FDA approval for the Phase II study on obesity treatment with BIO101 has the potential to significantly impact Biophytis' future trajectory and market performance.

Biophytis SA has obtained FDA approval to start its phase 2 OBA study in obesity with BIO101, focusing on muscle strength improvement in lower limbs. The FDA approval for the phase 2 OBA study in obesity has the potential to significantly impact Biophytis SA's future and market performance.

Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million. The exclusive license agreement with Blanver for BIO101 in Latin America has the potential to significantly impact Biophytis' future market performance and strategic trajectory.

Biophytis SA has filed an IND application with the US FDA for its phase 2 study in obesity with BIO101 (20-hydroxyecdysone). The study will assess the efficacy and safety of the drug in patients with obesity and overweight patients with secondary comorbidities. The filing of the IND application for the phase 2 study in obesity has the potential to significantly impact Biophytis SA's future and market performance by addressing a large addressable market size and attracting potential pharma partners.

Biophytis SA to hold Combined General Meeting on June 24, 2024 in Paris. The outcome of the General Meeting may moderately influence the company's future operations and market performance.

Biophytis announces design of phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). The announcement of the phase 2 study and potential results in 2025 could significantly impact Biophytis' future and market performance.

Biophytis SA is implementing a partnership strategy in obesity, seeking to license out BI0101 to pharmaceutical companies for development and commercialization. The partnership strategy in obesity has the potential to significantly impact Biophytis' future trajectory and market performance.

Biophytis SA's ADSs delisted from Nasdaq, transferred to OTC Pink market for cost savings. The transfer of ADSs to OTC market may moderately influence the company's financial performance and market sentiment.

Biophytis SA announces ratio change for its American Depositary Receipt program, increasing the ratio of ADSs to ordinary shares. The ratio change is expected to have a moderately noticeable influence on the company's future performance and market dynamics.

Biophytis forms new Scientific Advisory Board for phase 2 OBA clinical study in obesity, plans to file IND with FDA soon. Formation of new Scientific Advisory Board and IND filing for phase 2 study expected to have significant impact on Biophytis' future and market performance.

Biophytis SA announces 2023 financial results and updates on business activities, including progress in clinical programmes and financial figures. The article describes significant developments in clinical programmes, financial results, and partnerships that could have a significant impact on Biophytis SA's future trajectory and market performance.

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone). The launch of a new clinical development program with promising preclinical results in obesity could significantly impact Biophytis' future and market performance.

Biophytis SA announces approval of all resolutions presented at the Combined General Meeting. Resolutions approved at the meeting may moderately influence the company's financial performance and operations.

Biophytis presented its phase 3 protocol for the treatment of sarcopenia at a conference in the USA. The phase 3 protocol presentation and potential drug candidate advancements could significantly impact Biophytis' future and market performance.

Biophytis received Nasdaq notice due to low stock price, has 180 days to regain compliance. The notification may moderately affect the company's financial performance and market sentiment.